About TARGET PharmaSolutions
TARGET PharmaSolutions is a company based in Chapel Hill (United States) founded in 2015 by Meg Boothpowell and Michael Fried was acquired by Norwest Venture Partners in June 2016. TARGET PharmaSolutions has raised $2 million across 1 funding round from investors including Novartis, Boehringer Ingelheim and Allergan.
- Headquarter Chapel Hill, United States
- Founders Meg Boothpowell, Michael Fried
- Email••••••••
- Phone•••• ••••
- Website targetpharmasolutions.com
- Social LinkedIn
- Acquired by Norwest Venture Partners (Jun 2016)
- Total Equity Funding$2M (USD)
in 1 rounds
- Latest Funding Round$2M (USD), Series A
Jan 2016
- InvestorsNovartis
& 6 more
- Acquired byNorwest Venture Partners
(Jun 2016)
Funding Insights of TARGET PharmaSolutions
TARGET PharmaSolutions has successfully raised a total of $2M through 1 strategic funding round. The most recent funding activity was a Series A round of $2 million completed in January 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $2M
- Total Rounds 1
- Last Round Series A — $2M
- First Round $2M
(Jan 2016)
- Investors Count 2
All 1 funding rounds of TARGET PharmaSolutions with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2016 | $2M | Series A | – | Rex Health Ventures |
7 investors in total: 7 institutional.
Investors in TARGET PharmaSolutions
TARGET PharmaSolutions has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Novartis, Boehringer Ingelheim and Allergan.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | rexhealthventures.com | - | |
Early-stage ventures in the Southeast are supported by VentureSouth. | 2014 | venturesouth.vc | Greenville, United States | |
Venture capital and growth equity firm providing investments and resources to entrepreneurs in various sectors. | 1961 | nvp.com | Menlo Park, United States | |
A portfolio of generic medicines is developed and manufactured. | 1948 | allergan.com | Madison, United States | |
Generic drugs and clinical research services are provided globally. | 1885 | boehringer-ingelheim.com | - | |
R&D focused on manufacturing of drugs for multiple therapeutic areas | 1996 | novartis.com | Basel, Switzerland | |
Offers independent investigative journalism on politics, justice, technology, and immigration issues. | 2014 | theintercept.com | New York, United States |
Investor details for TARGET PharmaSolutions
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of TARGET PharmaSolutions
16 people are tracked at TARGET PharmaSolutions (11 in leadership, 4 in board & advisors, 1 in team).
| Name | Role | Group |
|---|---|---|
Meg Boothpowell | Co-Founder | Leadership |
Michael Fried | Co-Founder & Scintific Advisor | Leadership |
Michael Mckelvey | CEO | Leadership |
Michael W. Fried | Co-Founder & Chief Medical Officer | Leadership |
Joy Peter | VP, Evidence Solutions | Leadership |
Tara Bridgeman | Senior Director, Human Resources | Leadership |
Julie Mallory Crawford | VP, RWE & Strategic Partnerships | Leadership |
Matt Roth | VP, Finance | Leadership |
Alan Brookhart | Chief Scientific Officer | Leadership |
Rob Sullivan | Chief Data & Analytics Officer | Leadership |
Nathan Nussbaum | Head Of Data Innovation | Leadership |
Meg Powell | Co-Founder & Chair | Board & advisors |
Eric Edell | Board Member | Board & advisors |
Andrew Von Eschenbach | Senior Advisor | Board & advisors |
Franz Humer | Senior Advisor | Board & advisors |
Sonia Li | Board Observer | Team |
Complete people profiles for TARGET PharmaSolutions
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of TARGET PharmaSolutions
3 dated milestones of TARGET PharmaSolutions across 1 years, from founding to its latest funding, stage changes and deals.
- Founded TARGET PharmaSolutions is founded.
- Funding First funding round of $2.0M.
- Exit Acquired by Norwest Venture Partners.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about TARGET PharmaSolutions
TARGET PharmaSolutions was founded in 2015 and raised its 1st funding round 1 year after it was founded.
TARGET PharmaSolutions is headquartered in Chapel Hill, United States. It is registered at Chapel Hill, North Carolina, United States.
Michael Mckelvey is the current CEO of TARGET PharmaSolutions.
TARGET PharmaSolutions is a funded company, having raised a total of $2M across 1 funding round to date. The company's 1st funding round was a Series A of $2M, raised on Jan 2016.
TARGET PharmaSolutions was established in 2015 in Chapel Hill, United States. Clinical data management and consulting services are delivered to support pharmaceutical operations. Focus is placed on data handling, analysis, and advisory expertise within the healthcare sector. The company is led by co-founders Meg Boothpowell and Michael Fried, alongside CEO Michael Mckelvey. Activities are centered in the U.S., addressing needs in clinical research and compliance.
TARGET PharmaSolutions has 7 investors. Key investors include Novartis, Boehringer Ingelheim, Allergan, Norwest Venture Partners, and Rex Health Ventures.
Yes. TARGET PharmaSolutions was acquired by Norwest Venture Partners in June 2016.